CN104053647B - 作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物 - Google Patents

作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物 Download PDF

Info

Publication number
CN104053647B
CN104053647B CN201280051009.4A CN201280051009A CN104053647B CN 104053647 B CN104053647 B CN 104053647B CN 201280051009 A CN201280051009 A CN 201280051009A CN 104053647 B CN104053647 B CN 104053647B
Authority
CN
China
Prior art keywords
alkyl
compound
disease
substituted
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280051009.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104053647A (zh
Inventor
约翰·P·托斯卡诺
达里尔·A·格思里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Priority to CN201810435608.5A priority Critical patent/CN108409662B/zh
Publication of CN104053647A publication Critical patent/CN104053647A/zh
Application granted granted Critical
Publication of CN104053647B publication Critical patent/CN104053647B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201280051009.4A 2011-10-17 2012-10-16 作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物 Expired - Fee Related CN104053647B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810435608.5A CN108409662B (zh) 2011-10-17 2012-10-16 作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161548036P 2011-10-17 2011-10-17
US61/548,036 2011-10-17
PCT/US2012/060425 WO2013059194A1 (en) 2011-10-17 2012-10-16 Meldrum 's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810435608.5A Division CN108409662B (zh) 2011-10-17 2012-10-16 作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物

Publications (2)

Publication Number Publication Date
CN104053647A CN104053647A (zh) 2014-09-17
CN104053647B true CN104053647B (zh) 2018-06-01

Family

ID=47143299

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810435608.5A Expired - Fee Related CN108409662B (zh) 2011-10-17 2012-10-16 作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物
CN201280051009.4A Expired - Fee Related CN104053647B (zh) 2011-10-17 2012-10-16 作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201810435608.5A Expired - Fee Related CN108409662B (zh) 2011-10-17 2012-10-16 作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物

Country Status (13)

Country Link
US (3) US9181213B2 (enExample)
EP (1) EP2776402B1 (enExample)
JP (1) JP6177246B2 (enExample)
KR (1) KR102061537B1 (enExample)
CN (2) CN108409662B (enExample)
AU (2) AU2013201929B2 (enExample)
BR (1) BR112014009282B1 (enExample)
CA (1) CA2852914C (enExample)
HK (1) HK1200168A1 (enExample)
IL (1) IL232101A (enExample)
MX (1) MX363306B (enExample)
SG (1) SG11201401587QA (enExample)
WO (1) WO2013059194A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181213B2 (en) 2011-10-17 2015-11-10 The Johns Hopkins University Meldrum's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as HNO donors
BR112015017251B1 (pt) 2013-01-18 2021-10-26 Cardioxyl Pharmaceuticals, Inc. Composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas
EP3126329B1 (en) 2014-01-17 2019-05-29 Cardioxyl Pharmaceuticals Inc. N-hydroxymethanesulfonamide nitroxyl donors
ES2749682T3 (es) * 2014-05-27 2020-03-23 Cardioxyl Pharmaceuticals Inc Derivados de pirazolona como donadores de nitroxilo
US9464061B2 (en) * 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
WO2015183838A1 (en) 2014-05-27 2015-12-03 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors
ES2871079T3 (es) 2015-06-26 2021-10-28 Univ Johns Hopkins Acidos hidroxámicos N-sustituidos con grupos salientes a base de carbono como donantes eficaces de HNO y usos de los mismos
WO2017070084A1 (en) 2015-10-19 2017-04-27 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as nitroxyl donors
EP3365328A1 (en) * 2015-10-19 2018-08-29 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
EP3490975B1 (en) * 2016-07-28 2021-05-05 The Johns Hopkins University O-substituted hydroxamic acids
EP3565544A1 (en) 2017-01-03 2019-11-13 Cardioxyl Pharmaceuticals Inc. Method of administering nitroxyl donating compounds
RS63124B1 (sr) 2018-03-08 2022-05-31 Incyte Corp Aminopirazin diol jedinjenja kao pi3k-y inhibitori
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
US11912647B2 (en) 2020-05-22 2024-02-27 University Of Georgia Research Foundation, Inc. Diversity-oriented synthesis of N,N,O-trisubstituted hydroxylamines from alcohols and amines by N—O bond formation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038947A1 (en) * 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
CN101472576A (zh) * 2006-03-17 2009-07-01 约翰斯·霍普金斯大学医学院 作为新的有生理学价值的硝酰氧基供体的n-羟基磺酰胺衍生物
CN102076342A (zh) * 2008-05-07 2011-05-25 卡尔迪奥克斯尔制药公司 作为硝酰基供体的新亚硝基化合物及其使用方法
US20110136827A1 (en) * 2009-12-07 2011-06-09 Toscano John P Bis-Acylated Hydroxylamine Derivatives

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3751255A (en) 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4539321A (en) 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
DE3583799D1 (de) 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
US4663351A (en) 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
US6525081B1 (en) 1997-10-24 2003-02-25 Shionogi & Co., Ltd. Antirheumatic
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
WO2000006128A1 (fr) 1998-07-28 2000-02-10 Tanabe Seiyaku Co., Ltd. Preparation capable de liberer un medicament au niveau d'un site cible dans l'intestin
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
GB0114223D0 (en) 2001-06-12 2001-08-01 Ici Plc Catalytic oxidation process
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
JP2007514759A (ja) 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
EP1718621A4 (en) 2004-01-30 2009-08-19 Univ Johns Hopkins NITROXYL PREPARATION COMPOUNDS APPLICATION METHOD
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
CA2613477C (en) 2005-06-23 2013-12-03 Johns Hopkins University Thiol-sensitive positive inotropes
EP2010476A4 (en) 2006-04-13 2011-01-26 Univ Wake Forest Health Sciences NITROXYL DISPENSERS FROM C-NITROSO COMPOUNDS
JP2011502105A (ja) 2007-09-26 2011-01-20 ジョンズ ホプキンス ユニバーシティ 新規で生理学的に有用なニトロキシル供与体としてのｎ−ヒドロキシルスルホンアミド誘導体
WO2011063339A1 (en) 2009-11-23 2011-05-26 Cardioxyl Pharmaceuticals, Inc. Nitroxyl donors for the treatment of pulmonary hypertension
CN102753520B (zh) 2009-12-07 2016-06-08 约翰斯霍普金斯大学 N-酰氧基磺酰胺和n-羟基-n-酰基磺酰胺衍生物
US9181213B2 (en) 2011-10-17 2015-11-10 The Johns Hopkins University Meldrum's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as HNO donors
BR112015017251B1 (pt) 2013-01-18 2021-10-26 Cardioxyl Pharmaceuticals, Inc. Composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
ES2749682T3 (es) 2014-05-27 2020-03-23 Cardioxyl Pharmaceuticals Inc Derivados de pirazolona como donadores de nitroxilo
WO2015183838A1 (en) 2014-05-27 2015-12-03 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038947A1 (en) * 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
CN101472576A (zh) * 2006-03-17 2009-07-01 约翰斯·霍普金斯大学医学院 作为新的有生理学价值的硝酰氧基供体的n-羟基磺酰胺衍生物
CN102076342A (zh) * 2008-05-07 2011-05-25 卡尔迪奥克斯尔制药公司 作为硝酰基供体的新亚硝基化合物及其使用方法
US20110136827A1 (en) * 2009-12-07 2011-06-09 Toscano John P Bis-Acylated Hydroxylamine Derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Development of N-Substituted Hydroxylamines as Efficient Nitroxyl (HNO) Donors;Daryl A. Guthrie等;《Journal of American Chemistry Society》;20120201;第134卷(第4期);第1962-1965页 *
Production of nitroxyl(HNO) at biologically relevant temperatures from the retro-Diels-Alder reaction of N-hydroxyurea-derived acyl nitroso-9,10-dimethylanthracene cycloadducts;Yueping Xu等;《Tetrahedron Letters》;20000608;第41卷(第22期);第4265-4269页 *

Also Published As

Publication number Publication date
WO2013059194A1 (en) 2013-04-25
US20160115148A1 (en) 2016-04-28
BR112014009282B1 (pt) 2021-12-14
US9862699B2 (en) 2018-01-09
SG11201401587QA (en) 2014-07-30
CA2852914C (en) 2019-11-26
US20170050947A1 (en) 2017-02-23
EP2776402A1 (en) 2014-09-17
MX363306B (es) 2019-03-20
HK1200168A1 (en) 2015-07-31
JP2015501308A (ja) 2015-01-15
EP2776402B1 (en) 2017-07-26
BR112014009282A8 (pt) 2020-04-22
AU2013201929A1 (en) 2013-05-02
AU2015246114A1 (en) 2015-11-12
MX2014004596A (es) 2014-09-04
CA2852914A1 (en) 2013-04-25
AU2013201929B2 (en) 2015-07-23
US9499511B2 (en) 2016-11-22
JP6177246B2 (ja) 2017-08-09
KR20140107197A (ko) 2014-09-04
CN108409662A (zh) 2018-08-17
IL232101A (en) 2017-04-30
KR102061537B1 (ko) 2020-01-03
CN108409662B (zh) 2021-10-26
BR112014009282A2 (pt) 2017-06-13
US9181213B2 (en) 2015-11-10
US20140275134A1 (en) 2014-09-18
CN104053647A (zh) 2014-09-17
IL232101A0 (en) 2014-05-28

Similar Documents

Publication Publication Date Title
CN104053647B (zh) 作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物
CN102753519B (zh) 二酰基化的羟基胺衍生物
JP5826762B2 (ja) Ｎ−アシルオキシスルホンアミドおよびｎ−ヒドロキシ−ｎ−アシルスルホンアミド誘導体
US10577384B2 (en) Substituted asymmetric ureas as modulators of ghrelin receptor activity
CN104557863B (zh) 一种新型烟酰胺磷酸核糖转移酶抑制剂及其合成方法与应用
US20240327418A1 (en) Multi-target inhibitor targeting hdac and nad synthesis and use of multi-target inhibitor
JP2018537419A (ja) ニトロキシルドナーとしてのｎ−ヒドロキシルスルホンアミド誘導体
CN107531634A (zh) 作为wnt信号通路抑制剂的3‑氨基甲酰基苯基‑4‑甲酰胺和间苯二甲酰胺衍生物
CN107922371A (zh) 作为有效的hno供体的具有碳基离去基团的n‑取代的异羟肟酸及其用途
CN108064222A (zh) N-苯基-(吗啉-4-基或哌嗪基)乙酰胺衍生物及其作为wnt信号通路抑制剂的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180601

CF01 Termination of patent right due to non-payment of annual fee